Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
02/21/2008
Trade Name:
Humira
Generic or Proper Name (*):
adalimumab
Indications Studied:
Treatment of juvenile idiopathic arthritis
Therapeutic Category:
Anti-inflammatory
Ages Studied:
4 years and older
Study #:
1
Study Type:
Efficacy/Safety/Pharmacokinetic
Study Design:
Open Label/Blind/Placebo/Parallel Group/Population Pharmacokinetic
No Patients:
171
No Centers:
31
No Countries:
8
BPCA(B), PREA(P):
P
-
-